Mallinckrodt v. Baxter: IV Acetaminophen Patent Dispute Dismissed Without Prejudice
Mallinckrodt Pharmaceuticals Ireland brought a four-patent infringement action against Baxter International over Ofirmev® acetaminophen injection 10 mg/mL in the Delaware District Court. The parties jointly stipulated to dismiss all claims without prejudice after 179 days, with each side bearing its own costs.
Mallinckrodt’s IV Acetaminophen Portfolio Dispute Ends in Mutual Walkaway
Filed on 13 September 2024 in the U.S. District Court for the District of Delaware, this infringement action saw Mallinckrodt Pharmaceuticals Ireland, Ltd. assert four patents — US10383834B2, US9610265B2, US9987238B2, and US9399012B2 — against Baxter International, Inc. The patents cover intravenous acetaminophen injection formulations, specifically the 10 mg/mL product marketed under the Ofirmev® brand. Delaware was a predictable venue choice given the state’s status as a preferred forum for pharmaceutical patent disputes.
The case closed on 11 March 2025 via a jointly filed stipulation of dismissal without prejudice, approved by Judge Gregory B. Williams. All claims and counterclaims between the parties were terminated, and each party agreed to bear its own legal costs and fees. Crucially, a dismissal without prejudice means neither the patents nor the infringement allegations have been adjudicated on the merits — Mallinckrodt retains the full legal right to refile these claims in future proceedings.
The 179-day resolution is notably swift for a multi-patent pharmaceutical infringement action, suggesting the parties likely reached a commercial accommodation — potentially a licensing arrangement or supply agreement — outside the public record. The court retained jurisdiction to enforce the stipulation, which is a standard mechanism providing a backstop if the underlying commercial terms are breached. The precise terms of any settlement remain undisclosed.
Filing to Dismissed without Prejudice in 179 days
179 days — faster than the median ANDA/pharma patent case in Delaware, which typically exceeds 2 years
Dismissed without prejudice: what the stipulated order means for both parties
Stipulated dismissal without prejudice — no merits ruling
A stipulated dismissal without prejudice under FRCP Rule 41 means the court has made no finding on infringement, validity, or damages. The case is removed from the docket by mutual agreement, but neither party is bound by a merits judgment. The court’s retained jurisdiction clause is a practical safeguard: if the parties have agreed commercial terms, breach of those terms can be enforced without starting fresh litigation.
No merits adjudicationMallinckrodt preserves all four patents for future enforcement
Because the dismissal is without prejudice, Mallinckrodt’s infringement claims survive intact. None of the four asserted patents — including the lead patent US10383834B2 — have been invalidated, limited, or adjudicated. Mallinckrodt can refile against Baxter or assert the same patents against other IV acetaminophen manufacturers. This outcome is consistent with a plaintiff that secured satisfactory commercial terms rather than litigating to judgment.
Right to refile preservedBaxter exits without an invalidity finding or damages award
Baxter faces no adverse judgment on infringement and has not been ordered to pay damages or royalties by court decree. However, without a finding of invalidity or non-infringement, Baxter cannot point to this case as establishing freedom to operate. Any ongoing or future commercialisation of IV acetaminophen 10 mg/mL products will still need to be assessed against Mallinckrodt’s patent portfolio, which remains fully intact and enforceable.
No invalidity finding securedIV acetaminophen market: patent cloud remains over generic entrants
The without-prejudice dismissal leaves Mallinckrodt’s four-patent IV acetaminophen portfolio fully operative as a competitive barrier. Other manufacturers eyeing the Ofirmev® space cannot draw comfort from this outcome — there is no precedent of invalidity or non-infringement to rely on. The swift resolution and mutual cost-bearing suggest a negotiated accommodation, but the confidential nature of any terms means the competitive landscape remains uncertain for third-party generic entrants.
Patent barrier remains activeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | MALLINCKRODT PHARMACEUTICALS IRELAND, Ltd. | Company | Pharmaceutical IP licensor — holder of US10383834B2 and three related IV acetaminophen patentsSearch in Eureka ↗ |
| Defendant | Baxter International, Inc. | Company | Baxter International, Inc. — global medical products manufacturer and IV drug supplierSearch in Eureka ↗ |
| Plaintiff counsel | Kelly E. Farnan | Attorney | Counsel for MALLINCKRODT PHARMACEUTICALS IRELAND, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sara M. Metzler | Attorney | Counsel for MALLINCKRODT PHARMACEUTICALS IRELAND, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Richards Layton & Finger PA | Law Firm | Representing MALLINCKRODT PHARMACEUTICALS IRELAND, Ltd.Search in Eureka ↗ |
| Defendant counsel | Philip A. Rovner | Attorney | Counsel for Baxter International, Inc.Search in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Baxter International, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order dismisses all claims and counterclaims without prejudice, with each party bearing its own costs. The phrasing is deliberately bilateral and neutral — neither party concedes infringement, invalidity, or damages liability. The court’s retained jurisdiction clause is legally significant: it converts the dismissal into a quasi-consent order, allowing enforcement of any undisclosed commercial terms without initiating fresh proceedings. This structure is consistent with a negotiated resolution rather than a litigated outcome.
US10383834B2 — Intravenous Acetaminophen Injection Formulation Portfolio
The four asserted patents — US10383834B2, US9610265B2, US9987238B2, and US9399012B2 — collectively cover formulation, composition, and method-of-use aspects of intravenous acetaminophen at the 10 mg/mL concentration associated with the Ofirmev® brand. The application dates span from US12/270796 (an earlier priority chain) through to US15/979154, suggesting a deliberate continuation strategy designed to extend patent coverage across successive formulation and process claims as the product matured commercially.
Ofirmev® (IV acetaminophen) occupies a strategically important position in hospital formularies as a non-opioid analgesic option, making its patent estate commercially significant. Mallinckrodt’s multi-patent approach — layering composition, formulation stability, and method claims across four patents — creates a high invalidation burden for any challenger. For competitors developing IV acetaminophen generics, each patent family represents a separate clearance obligation, and the absence of any court ruling on validity means the risk profile of this portfolio remains unresolved.
Should your IV acetaminophen product be cleared against US10383834B2?
Any company developing, manufacturing, or commercialising an intravenous acetaminophen 10 mg/mL injection product in the United States should treat Mallinckrodt’s four-patent portfolio as a live enforcement risk. This case produced no invalidity ruling and no non-infringement finding — the patent estate is fully intact. ANDA filers, 505(b)(2) applicants, and hospital-supply generics manufacturers are all within scope of potential assertion.
PatSnap Eureka’s FTO Search Agent enables your team to map claim scope across all four patent families, identify continuation and divisional applications that may extend coverage, and flag international counterparts relevant to ex-US manufacturing or supply chains. Run a targeted FTO analysis on US10383834B2, US9610265B2, US9987238B2, and US9399012B2 before any regulatory filing or product launch decision in the IV analgesic formulation space.
Run a freedom-to-operate analysis on US10383834B2 to assess your product’s exposure
Run FTO in Eureka →Similar IV pharmaceutical patent infringement cases in Delaware District Court
Explore comparable intravenous pharmaceutical formulation patent disputes filed in the Delaware District Court, including multi-patent ANDA and infringement actions.
What this case signals for the IV pharmaceutical patent IP landscape
A fast, cost-neutral dismissal in a multi-patent pharma case rarely means resolution — it typically means the real deal was done elsewhere.
Without-prejudice dismissals mask commercial outcomes — monitor for re-filing
When a pharma plaintiff dismisses without prejudice this quickly, it typically signals a licensing deal or supply arrangement was reached off-record. IP teams tracking Mallinckrodt’s portfolio should monitor for re-filing against other IV acetaminophen manufacturers, as the patents remain fully enforceable and the strategy may simply be shifting targets.
Four-patent stacking around a single product amplifies licensing leverage
Mallinckrodt asserted four distinct patents covering the same IV acetaminophen formulation. This portfolio stacking — spanning multiple application families — makes it procedurally and commercially costly for defendants to challenge all claims simultaneously. R&D teams working in the IV analgesic space should map each patent family independently rather than treating them as a single clearance hurdle.
MALLINCKRODT v Baxter — key questions answered
Mallinckrodt asserted four U.S. patents: US10383834B2, US9610265B2, US9987238B2, and US9399012B2. All four cover aspects of intravenous acetaminophen injection formulations at 10 mg/mL, associated with the Ofirmev® branded product. The case was filed in the Delaware District Court on 13 September 2024.
The case was dismissed pursuant to a joint stipulation by both parties, approved by Judge Gregory B. Williams. A without-prejudice dismissal means no merits ruling was made. The public record does not disclose the reasons, but the swift 179-day timeline and mutual cost-bearing arrangement are consistent with the parties reaching a confidential commercial resolution, such as a licensing agreement.
Not definitively. A dismissal without prejudice produces no finding of non-infringement or invalidity. Mallinckrodt’s four patents remain fully enforceable, and the dismissal does not constitute a legal clearance for Baxter or any other manufacturer. Any future IV acetaminophen product commercialisation would still require independent freedom-to-operate analysis against the surviving patent portfolio.
Yes. A dismissal without prejudice expressly preserves the plaintiff’s right to refile. Mallinckrodt can reassert the same four patents against Baxter in a new action, subject to applicable statutes of limitations and any commercial terms agreed in the undisclosed settlement. The court also retained jurisdiction to enforce the stipulation, providing an additional mechanism short of full re-litigation.
Ofirmev® is the branded intravenous formulation of acetaminophen at 10 mg/mL, used in hospital settings as a non-opioid analgesic. Its clinical importance in pain management — particularly in opioid-reduction protocols — gives its patent estate significant commercial value. Mallinckrodt’s four-patent portfolio covering this product’s formulation and use creates substantial barriers for generic entrants seeking to offer competing IV acetaminophen products.
PatSnap Eureka searches patents and litigation data to answer instantly.